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LRYGB had the greatest lifetime costs at every age ($13,506 vs. no treatment, $3,859
vs. LAGB), but also the greatest amount of QALYs gained (2.54 more vs. no treat-
ment, 1.32 vs. LAGB), leading to a lower ICER than LAGB when compared with no
treatment ($5,324 and $7943/QALY, respectively). When LRYGB was compared to
LAGB, a relatively low ICER of $2,918/QALY resulted at age 40. ICERs in both compari-
sons increased steadilywith age. In one-way sensitivity analyses for LRYGBagainst no
treatment, the most sensitive parameters were medical costs associated with initial
baseline BMI (ICER varied 187%), and medical costs associated with LRYGB efficacy
(80%). The results of LAGB against no treatment were similar, although utility asso-
ciated with efficacy was much more sensitive in comparison. In results for LRYGB
versus LAGB, the model was most sensitive to recurring medical cost parameters
associated with efficacy of treatment. CONCLUSIONS: Both LRYGB and LAGB were
found to be cost-effective compared to no treatment for morbidly obese people,
with ICERs below $25,000 up to age sixty. These results were robust to reasonable
model parameter changes. This study also suggests that LRYGBmay bemore cost-
effective than LAGB due to the relative improvement in QALYs gained.
PSU25
CLINICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY FOR OBESE
PATIENTS: ECONOMIC EVALUATION IN SOUTH KOREA
Song HJ, Lee HJ, Lee JY, Choi JE, Oh SH, Kwon JW
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: To evaluate the cost-effectiveness of bariatric surgery in obese Ko-
rean people. METHODS: The target population was obesity patients defined as
having a body mass index (BMI) of BMI30kg/m2 with diabetes. This study per-
formed in Healthcare system perspectives. The bariatric surgery comprised lapa-
roscopic adjustable gastric banding (LAGB), Roux-en Y gastric bypass (RYGB), and
Sleeve gastrectomy (SG). The comparison, non-surgical treatments consisted of
physician visit, exercise, diet, and pharmacotherapy. For cost-effectiveness anal-
ysis, the decision model with a one year time horizon was used. The effectiveness
associated with percent weight change from baseline, BMI reduction, and propor-
tion of patients with more than 10% weight change. The cost data was collected
from the survey of 9 medical centers who had conducted these obesity treatments
and Korean national health insurance statistics, based on 2011 costs. The effective-
ness data and distribution of surgery and complication was collected from 7multi-
center, 485 patients retrospective chart review. Incremental cost-effectiveness ra-
tio (ICER) of bariatric surgery compared to non-surgery interventions was
calculated in obese people. Subgroup analysis using various BMI levelwith/without
diabetes and probability sensitivity analysis were conducted to assess the stability
of base-case results. RESULTS: The bariatric surgery had higher cost (US$9273) and
better effectiveness(18.1% weight loss), the Incremental cost-effectiveness ratio
(ICER) was US$512 per one-percent weight loss. Through the subgroup and sensi-
tivity analysis under various conditions, robustness of the study results was also
demonstrated. CONCLUSIONS: The cost-effectiveness study for clinical outcomes
indicated that bariatric surgery was clinical and cost effective alternative to con-
ventional therapy in obese patients.
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OBJECTIVES: The purpose of this study was to assess the cost-utility of bariatric
surgery compared to non-surgical interventions in obese Korean people.
METHODS: We used Markov model comparing the lifetime expected costs and
quality adjusted life years (QALY) between bariatric surgery and non-surgery in-
tervention from Korean Healthcare system perspectives. Our target cohort con-
sisted of obese people defined as having a body mass index (BMI) of 30-40 in South
Korea. The starting age of cohort was 30 years old. The non-surgical interventions
include physician visit, exercise, diet, and pharmacotherapy. The cycle length was
1 year and used half-cycle correction. The health status comprised five states such
as no comorbidity, mild/moderate comorbidity (diabetes or/and hypertension or/
and, dyslipidemia), severe comorbidity (CHD or/and stroke), death due to CVD, and
death due to other cause. Input data of transition probability for eachdisease status
and utility weight calculated from the relationship between weight loss and QALY
gain using Korean National Health and Nutrition Examination Survey data. The
rate of death due to CVD and other cause were calculated Korean death statistics.
The cost datawas collected from the survey of 9medical centerwhohad conducted
those obesity treatments and Korean national health insurance statistics, based on
2011 costs. Discount of 5% was applied in cost and QALY. Incremental cost-effec-
tiveness ratio (ICER) of bariatric surgery compared to non-surgery interventions
was calculated. RESULTS: The cost-utility study indicated that bariatric surgery
had US$1,522 Incremental costs and 0.86 Incremental QALY compared non-surgi-
cal interventions. Through the base case analysis, ICER was US$1771/QALY. The
sensitivity analyses under a variety of assumption, robustness of the study results
were also demonstrated. CONCLUSIONS: The study indicated that bariatric sur-
gery was cost-effective alternative to non-surgical interventions over lifetime, pro-
viding substantial lifetime benefits in obese Korean people.
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OBJECTIVES: To assess differences in demographics, comorbidities, and healthcare
costs and utilization among patients undergoing total hip replacement (THR) surgery
with and without muscle atrophy/weakness (MAW).METHODS: Using large US ad-
ministrative claims databases, we examined individuals aged 50 with commer-
cial insurance or Medicare supplemental insurance whowere hospitalized for THR
between January 2006 to September 30, 2009. The first hospitalization was defined
as the index stay. Three cohorts were further identified based on whether individ-
uals had medical claims associated with MAW over the 12 months pre-index stay
(pre-MAW), patients whose first MAW claim occurred during or within the 12
months after the index stay (post-MAW), or patients without any MAW claim (no-
MAW). Demographics and comorbidities during 1 year prior to the index stay, and
health care utilization and costs during 1 year before and after the index stay were
compared among groups. Multivariate regressions were performed to estimate
1-year post-indexmedical costs controlling for cross-cohort differences. RESULTS:
There were 23,127 commercially-insured (pre-MAW: 323; post-MAW: 1,176; no-MAW:
21,628) and19,607Medicare (pre-MAW:332;post-MAW:909;no-MAW:18,366)patients
identified. Compared with commercially-insured patients in the post-MAW and no-
MAW cohorts, individuals in the pre-MAW cohort were more likely to have any hos-
pitalization during the 12 months pre-index stay (33.4% vs. 12.7% vs. 10.5%; both
p0.05), ahigherCharlsoncomorbidity indexscore (5.5vs. 4.3vs. 3.9; bothp0.05), and
higher total costs ($35,022 vs. $15,011 vs. 12,952; both p0.05). Controlling for cross-
cohort differences, both pre-MAW and post-MAW cohorts had significantly higher
totalhealthcare costs ($6697and$8593) than theno-MAWcohort (bothp0.01) during
the 12 months post-index stay. Similar trends were observed in the Medicare
population. CONCLUSIONS: Among US patients receiving THR surgery, those with
MAW had higher health care costs than patients without MAW.
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OBJECTIVES: This is an exploratory analysis of potential variables associated with
roux-en-Y gastric bypass (RYGB) surgery hospitalization resource use pattern.
METHODS: Cross-sectional study based on a public database (DATASUS) records.
Inclusion criteria were patients undergoing RYGB between January 2008 and June
2011. Dependent variableswere length of stay and ICUneed. Independent variables
were: gender, age at surgery (continuous or categorized as older/younger than 60),
hospital volume (high volume: 100 RYGB/year; low volume: 100 RYGB/year),
surgery at certified center of excellence (CoE) by the American Society forMetabolic
and Bariatric Surgery (ASMBS) (yes/no), year of hospitalization. Univariate and
multivariate analysis (logistic regression for ICU need and linear regression for
length of stay) were performed. RESULTS: Data from 13,069 surgeries were ana-
lyzed. 14.8% of patients were male, mean age 38.210.4 years, 52.2% undergone
surgery in a high volume hospital, 11.6% from a certified CoE by ASMBS. In the
univariate analysis of potential factors associated with outcomes of interest, the
variable with highest effect size for length of stay was hospital volume (high vol-
ume 3.81.8 days vs 6.37.6 low volume, p0.001), whereas for ICU need it was
certified CoE (50.0% vs. 1.3%, p0.001). Final model for ICU need after logistic re-
gression includes certified CoE (OR 0.009, CI95% 0.006-0.014), hospital volume (OR
3.16, CI95% 2.93-3.41) and age group (OR 1.93, CI95% 1.46-2.57). Themost important
variable in the final model for log-transformed length of stay is hospital volume
(adjusted coefficient -0.338, CI95% -0.379 to -0.297); association was also found for
certified CoE, gender and age. In high volume hospitals, variance of RYGB length of
stay is significantly lower than variance in low volume hospitals (SD 2.1 vs. 11.0,
p0.001). CONCLUSIONS: High volume hospitals are strongly associated with
shorter length of stay and less variability, and ASMBS certification is strongly as-
sociated with less need for ICU.
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OBJECTIVES: Correct clinicalmanagement ofmorbid obese patients does not begin
and neither ends with bariatric surgery. The aim of this study was to evaluate the
association between number of medical follow-up visits after surgery and patient
outcomes in morbid obese patients undergoing roux-en-Y gastric bypass (RYGB).
METHODS: This is a database (DATASUS) retrospective cohort study. Inclusion
criteria was patients undergoing RYGB between January 2008 and June 2010with at
least one medical follow-up visit. The dependent variable was the Bariatric Anal-
ysis and Reporting Outcome System (BAROS) score, which combines clinical (%Ex-
cess weight loss, co-morbidity resolution) and quality of life outcomes in one cat-
egorical variable (failure/fair/good/very good/excellent). Independent variable was
adherence tomedical follow-up visits, adjusted for potential covariates. Univariate
and multivariate analysis (by linear regression) were performed at 12 and 24
A78 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
